Case studies › ISRG
The analyst note pile for ASML, Alibaba and Intuitive Surgical has one common flaw
Three notes, three sectors, one omission. Each carried a target price with a decimal point and no sensitivity against which to test it. Intuitive Surgical is the most useful of the three to take apart, because its input is disclosed and therefore falsifiable.
The company reports worldwide procedures across da Vinci and Ion up about 15%, da Vinci procedures up 14% and Ion up 31%. Third-quarter revenue rose 22% to US$3.05 billion. It is a genuinely good operating quarter.
What the quarter actually contains
| Line | Value |
|---|---|
| Revenue | $3.05bn, +22% |
| Worldwide procedures | +15% |
| da Vinci procedures | +14% |
| Ion procedures | +31% |
| da Vinci 5 placements | 315 (240 prior year) |
| Adjusted EPS | $3.00 (from $2.40) |
| GAAP EPS | $1.49 (from $1.95) |
| Antitrust settlement, pretax | $450m |
| EPS impact after tax | $0.99 |
| Forward 12m P/E | 37.13x |
| Industry forward P/E | 28.65x |
Adjusted EPS of US$3.00 against GAAP of US$1.49 is the same business read two ways. The 99 cents of difference is the settlement, and it is a real cost rather than an accounting artefact — cash leaves, and the settlement is subject to court approval.
The sensitivity that was missing
A note that targets a price off procedure growth has one input and should show it. Move the 15% procedure rate to 10% and hold pricing flat: instrument and accessory revenue — the recurring line that monetises utilisation — falls roughly a third relative to plan. System placements typically follow utilisation with a lag, because hospitals buy capacity they expect to fill.
Move it to 20% instead and the case requires operating-room capacity and trained surgeons that the installed base may not have. The constraint on the upside is not demand and it is not capital; it is theatre time and proctor availability.
That asymmetry is the point. The downside is arithmetic and the upside is a staffing constraint, and a target price that does not name either is a restatement of the current price.
The multiple is the actual position
37.13 times forward against an industry 28.65, Medtronic at 16.49 and Johnson & Johnson at 24.04. A 30% premium to the industry on a 15% procedure rate implies the market expects the rate to hold for a long time and the moat to hold longer.
The moat is real and it is switching cost rather than hardware: training, theatre workflow, instrument logistics and reliability. Hospitals do not swap platforms casually.
The moat is also the sensitivity nobody tables. Johnson & Johnson received De Novo authorisation for OTTAVA in July 2026, and Medtronic's Hugo is progressing. The first credible second-source in soft tissue changes hospital negotiating posture before it changes share, and posture is a pricing input.
The competition question, dated
Authorisation in July means the competitive front opened inside the same six months that produced a 7.8% price gain against a 28.7% industry gain. The stock underperformed its industry while beating the S&P 500's 2% decline, which reads as a de-rating partially offset by a recovery off the summer lows.
That is a stock already discounting some of the competition. The remaining question is whether the premium compresses to the industry or the industry re-rates to it.
Where the case breaks
For the premium: if procedure growth slows below 10%, the recurring revenue line compresses and a 37 times multiple on a decelerating base does not hold. The 15% is the number to watch and it is published every quarter.
For the discount: the settlement is one charge, but other litigation is pending and further charges would keep GAAP below adjusted and keep the quality of earnings in question. Court approval of the US$450 million is itself an open item.
And for the whole note: placements of 315 da Vinci 5 systems against 240 is adoption of the newest platform, which is a mix positive on system revenue and a training cost on the hospital. Both are true and only one is usually quoted.
What the arithmetic says
Procedures up 15%, revenue up 22%, adjusted EPS up 25%, GAAP EPS down 24%, a US$450 million charge, a 37.13 times multiple against 28.65 for the industry, and the first authorised soft-tissue competitor since July. Every one of those is disclosed and none of them is in a target price without a sensitivity.
Move the procedure rate 5 points either way and the case changes shape: down is arithmetic, up is theatre capacity. A target price that names neither is a decimal point, not a forecast.
Sources
Procedure, placement, revenue, earnings, charge and multiple figures are the company's reported third-quarter 2026 results and third-party multiple data. Peer multiples and the authorisation date are third-party. The procedure sensitivity and the theatre-capacity constraint are analytical and can be tested against published quarterly procedure rates.
Published for information only. Nothing here is investment advice or a recommendation. This note is not prepared in accordance with the legal requirements designed to promote the independence of investment research. No position is held in the security covered.